Acupuncture needles take on chemo sickness
NCT ID NCT07201194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding acupuncture and acupressure to standard anti-nausea medicine can better reduce chemotherapy-induced nausea. About 90 cancer patients with ongoing nausea will be split into two groups: one gets the extra acupuncture, the other gets medicine alone. Their nausea levels will be tracked over 22 days to see if the holistic approach makes a difference.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- acupuncture and acupressure
- What this could lead to
- If it works, this could offer a drug-free way to ease nausea during chemotherapy, improving quality of life for cancer patients.
- What could go wrong
- This is a small, early-stage trial with only 90 participants, so results may not apply to everyone. Acupuncture effects can vary, and the study relies on patient-reported outcomes, which are subjective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria * ≥ 18 years of age * Undergoing chemotherapy and experiencing nausea despite adherence to the prescribed antiemetic regimen * Understands and speaks Danish * Written and orally informed consent * Planned for treatment every 14 days * At least two chemotherapy cycles planned at the time of inclusion Exclusion Criteria: * Brain metastases * Performance status \>2
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Oncology, Vejle Hospital
RECRUITINGVejle, 7100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Comparison of efficacy and safety between hypofractionated and conventional fractionated radiotherapy after breast reconstruction in breast cancer patients: a phase III randomized controlled clinical trial
- EValuation of radIOLigand treatment in mEn with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T: phase I/II study
- A feasibility study on 5G-Enabled remote Robotic-Assisted Bronchoscopy-Guided cryoablation for pulmonary malignancies: a prospective, multicenter, Single-Arm clinical study (BRIDGE study)
- Omitting the boost to initially involved but undissected nodal stations that achieved clinical complete response after neoadjuvant systemic therapy in cN3 breast cancer: a phase III randomized study
- A study to evaluate the diagnostic performance of ACP3-Targeted PET imaging in patients with primary and recurrent prostate cancer: an Open-Label, Single-Arm, Single-Center study
- RIsk aDapted stereotactic radiotherapy vs. standarD of care radiotherapy in patients with prostate cancer in the adjuvant or saLvage sEtting with or without lymph node irradiation (RIDDLELN) - a phase III trial